Largest Multi-Centre Evaluation of Radioembolization Using Sir-Spheres for Patients With Inoperable Primary Liver Cancer Published in Hepatology
PAMPLONA, Spain, July 7, 2011 /PRNewswire/ --
Results of the multi-centre European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY) analysis of the long-term outcomes related to survival and safety of radioembolization using SIR-Spheres in patients with inoperable primary liver tumours were published on-line today in Hepatology, the peer-reviewed journal of the American Association of the Study of Liver Diseases.
Evaluation of 325 patients with inoperable primary liver cancer (unresectable hepatocellular carcinoma), who were treated by teams of liver specialists, oncologists, interventional radiologists and nuclear medicine physicians at eight centres in Germany, Italy and Spain, provided "robust evidence of the survival outcomes achieved with radioembolization, including patients with advanced disease and few treatment options," said Bruno Sangro, MD, PhD, Professor of Hepatology in the Liver Unit of the Clinical University of Navarra, Pamplona, Spain, and chair of the ENRY group.
About Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) occurs in people whose livers have become severely damaged or cirrhotic, due to conditions such as hepatitis and alcoholism. It is one of the ten most-common cancers in the world, with nearly 750,000 cases diagnosed annually, and the third-leading cause of cancer deaths. It occurs with greatest frequency in regions where hepatitis is most often diagnosed, such as in Asia Pacific and Southern Europe.
Hepatocellular cancer can be cured only by surgery, either by resecting the diseased parts of the liver, or by transplantation with a liver from a healthy donor. These interventions, however, are inappropriate for the great majority of patients, whose survival may range from a few months to two or more years depending largel